Bathi saben saham sajrone rolas wulan pungkasan: Alzamend Neuro Inc. (ALZN)

Analyzing the rolling annual EPS trend via the GURU.Markets chart, we see that the metric has reached the level of -2.31. The growth of Alzamend Neuro, Inc. (ALZN) shares is driven by the progress of candidates AL001 and AL002, patent protection, and M&A potential. The company is developing immunotherapy for Alzheimer's, relying on investor capital. However, the biotech's success depends on the outcome of early-stage trials and cost control prior to reaching profitability.
Rincian metrik keuangan lan pasar alzamend.com (ALZN)

Earnings per share (EPS) reflects the portion of total income allocated to a single common share. By analyzing EPS over the last four quarters, an investor can discern the actual efficiency of capital generation. This metric is calculated by dividing the total annual profit by the number of shares outstanding. For Alzamend Neuro, Inc. (ALZN), this figure depends not on market cycles, but on the success of clinical trials and the volume of venture financing.